Artrya Limited · ASX:AYA
Artrya — Investor Presentation (February 2025)
27 slides from Artrya's investor presentation, Feb 14, 2025
Slide 1: Presentation Deck Capital Raising
February 2025 ARTRYA Presentation Deck Capital Raising Not for Release to U.S. wire services or distribution in the United States 1
Slide 2: Important notice and disclaimer
Important notice and disclaimer IMPORTANT NOTICE AND DISCLAIMER The Presentation Materials contain summary information about the Company and its activities which is current as at the date of the Presentation Materials. The information in the Presentation Materials is of a These presentation material
Slide 3: Board of Directors, CEO, and Co-Founder
Board of Directors, CEO, and Co-Founder Chair Non-Executive Director Non-Executive Director Chief Executive Officer Co-founder Bernie Ridgeway Kate Hill Jacque Sokolov, MD Mathew Regan John Konstantopoulos Bernie brings a wealth of Ms Hill is an experienced non- Jacque J. Sokolov, MD, is Mat is an e
Slide 4: Executive Summary
Executive Summary • Every 40 seconds in the US, someone suffers a heart attack • Current practice for detecting coronary artery disease has not changed for decades • Our cloud-based, AI enabled software interrogates CCTA scans and provides the clinician with accurate, real-time information on the ex
Slide 5: A large, growing, and inadequately served market
A large, growing, and inadequately served market 5
Slide 6: Heart disease kills more people than all cancers combined
Heart disease kills more people than all cancers combined Outdated methods lead to suboptimal patient outcomes, unnecessary cost, and reduce system efficiency Old methods are ineffective Most procedures are unnecessary In detecting high high-risk plaques that 55% of invasive procedures are found to
Slide 7: Salix is unique in providing real-time patient diagnosis and triage
Salix® is unique in providing real-time patient diagnosis and triage Point of care enabling real-time plaque analysis Provides real-time analysis of CCTA scans. This includes quantitative plaque assessment, stenosis, calcium score, and FFR assessment* Single Reporting Platform Consolidates all CCTA
Slide 8: Seamlessly fits into workflow
Seamlessly fits into workflow Salix® is system agnostic and simple to deploy, use, and update Onsite Manual Assessment Review & Prepare Report Manual assessment | No plaque assessment | Limited access to reimbursement Offsite ‘Human in the loop’ Clinician Receives Report Requires two solutions for C
Slide 9: Salix is built to target all pillars across the care continuum
Salix® is built to target all pillars across the care continuum Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. Whole Heart Disease Structural Optimised Characterisation Severity Assessment Procedure Detailed Plaque and Dispersion Non-invasive Blood Flow Ass
Slide 10: Salix Demonstration
Salix® Demonstration ARTRYA
Slide 11: Backed by robust evidence and patents
Backed by robust evidence and patents Developed and trained on more than 5 million CT images Key Clinical Studies and Publications Coronary Artery Stenosis and High-Risk Plaque Assessed with Unsupervised Fully Automated Deep Learning Technique Evaluation of an artificial intelligence coronary artery
Slide 12: Market Adoption
Market Adoption 12
Slide 13: Heart disease is a large and growing health challenge
Heart disease is a large and growing health challenge 12.6 million CCTA scans (RoW)2 US$4.4 billion* Total Addressable Market (US) 6.2% YOY 4.4 Projected growth in Cardiac U.S. patients undergoing CCTA + Plaque Assessment million CCTA CCTA scans to 20281 scans2 Targeted Approach in US Greenfield • F
Slide 14: Key growth drivers for CCTA and FFR CT
Key growth drivers for CCTA and FFR CT Guidelines and Studies Reimbursement • ACC and AHA Guideline recognises CCTA and FFR CT • CMS has continued to recognise the need for FFR CT as the primary diagnostic pathway for suspected CAD and implemented appropriate payment policy • Leads to 41% reduction
Slide 15: Attractive SaaS pricing model
Attractive SaaS pricing model Hybrid approach subscription and fee-per-analysis pricing model based on volume with a highly attractive revenue-sharing pricing structure Revenue Model Benefits Tiered subscription • Positions Artrya as a single CCTA reporting platform Single platform for reporting CCT
Slide 16: Competitive Positioning
Competitive Positioning Salix® is fasted and places the specialist at the centre of care which is important for reimbursement Point of care (Highly scalable) • No Vulnerable Plaque assessment • Slow and manual assessment • Scale limited by business model • Access to reimbursement is time • Point of
Slide 17: Regulatory approval and pathway to revenue
Regulatory approval and pathway to revenue FDA Strategy Shortening the pathway to revenue 1. Salix Coronary Anatomy (submitted) • Agree pricing with existing US partners Estimated clearance end of 1Q CY2025 • Additional US agreements pre-FDA clearance with medium to large systems 2. Salix Coronary P
Slide 18: Strategic Agreements and Partnerships
Strategic Agreements and Partnerships Strategic Agreements Research Partnerships Research Partnerships • Three Strategic 5-year agreements to deploy Salix® upon FDA approval. • Artrya is in various stages of discussions with leading US healthcare systems and expect to have robust, committed pipeline
Slide 19: Significant Commercial Agreement
Significant Commercial Agreement Artrya secures multi-year commercial contract with Sonic Healthcare Australia Radiology Three-year commercial contract with Sonic Healthcare Australia - Radiology for use of Salix® Coronary Anatomy platform • Will generate revenue through a Software-as-a-Service (Saa
Slide 20: Flagship Novel Plaque Study - SAPPHIRE
Flagship Novel Plaque Study - SAPPHIRE Salix-based Analysis of Plaque to identify Patients at Higher Risk of Events The SAPPHIRE study will validate the novel Salix Plaque Dispersion Score to risk stratify patients based on individual plaques and improve treatment. Overview of Study Clinical and Com
Slide 21: Capital raising overview
Capital raising overview • A$15 million two tranche placement (Placement) to sophisticated and professional investors consisting of: Offer structure § ~A$5 million under the Company's placement capacity under ASX Listing Rules 7.1 and 7.1A; and and size § ~A$10 million subject to shareholder approva
Slide 22: Capital raising timetable
Capital raising timetable 1 Announcement of Offer 14 February 2025 Settlement Date – Tranche One Placement 19 February 2025 Allotment Date – Tranche One Placement 20 February 2025 General Meeting On or around 2 April 2025 Settlement Date – Tranche Two Placement 7 April 2025 Allotment Date – Tranche
Slide 23: Appendix One - Investment Risks
Appendix One - Investment Risks Set out in this section are the potential risks associated with Artrya, the Offer, the industry in which Artrya operates and an investment in Artrya shares. It is not an exhaustive list of every risk faced by Artrya now or in the future. The medical technology and dia
Slide 24: Appendix One - Investment Risks Continued
Appendix One - Investment Risks Continued A critical component of Artrya’s success is the ongoing retention of key personnel, specifically members of the management and product development teams. There is a risk that Artrya may not be able to attract and retain key personnel or be able to find effec
Slide 25: Appendix Two - International Offer Restrictions
Appendix Two - International Offer Restrictions This document does not constitute an offer of new ordinary shares in the Company (New Shares) pursuant to the Placement in any jurisdictions in which it would be unlawful. In particular, this document may not be distributed to any person, and the New S
Slide 26: Appendix Two - International Offer Restrictions
Appendix Two - International Offer Restrictions This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the “FMC Act”). The New Shares are not being offered or sold in New Zealand (or allotted with a view to
Slide 27: Thank You
Thank You ARTRYA